Richard Krasno - Opko Health Independent Director
| OPK Stock | 458.50 13.50 2.86% |
Director
Dr. Richard M. Krasno serves as Independent Director of the Company. Dr. Krasno was appointed to the Companys Board of Directors on February 9, 2017. Dr. Krasno was a private investor in companies for the past five years. Dr. Krasno also served as the executive director of the William R. Kenan, Jr. Charitable Trust from 1999 to 2014, and from 1999 to 2010, as President of the four affiliated William R. Kenan, Jr. Funds. Prior to joining the Trust, Dr. Krasno was the President of the Monterey Institute of International Studies in Monterey, California. From 2004 to 2012, Dr. Krasno also served as a Director of the University of North Carolina Health Care System and served as chairman of its board of directors from 2009 to 2012. From 1981 to 1998, he served as President and Chief Executive Officer of the Institute of International Education in New York. He also served as Deputy Assistant Secretary of Education in Washington, D.C. from 1979 to 1980. Dr. Krasno currently serves as a Director of Ladenburg Thalmann, Castle Brands, Inc. and BioCardia, Inc. since 2017.
| Age | 76 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Phone | 305 575 4100 |
| Web | https://www.opko.com |
Opko Health Management Efficiency
The company has return on total asset (ROA) of (0.0659) % which means that it has lost $0.0659 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1867) %, meaning that it generated substantial loss on money invested by shareholders. Opko Health's management efficiency ratios could be used to measure how well Opko Health manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Shmuel Rubinstein | Kamada | 78 | |
| Dov Ninveh | Elbit Systems | 71 | |
| Perry Nisen | Teva Pharmaceutical Industries | 63 | |
| Joe Cowan | Nice | 66 | |
| Murray Goldberg | Teva Pharmaceutical Industries | 74 | |
| Galia Maor | Teva Pharmaceutical Industries | 73 | |
| Tuvia Shoham | Kamada | 70 | |
| Ziv Kop | Kamada | 43 | |
| Dan Propper | Teva Pharmaceutical Industries | 73 | |
| Yigal Neeman | Elbit Systems | 73 | |
| Dan Falk | Nice | 74 | |
| Reuven Behar | Kamada | 60 | |
| Itzhak Krinsky | Kamada | 65 | |
| Rimon BenShaoul | Nice | 74 | |
| Gerald Lieberman | Teva Pharmaceutical Industries | 72 | |
| Yoram BenZeev | Elbit Systems | 74 | |
| Roberto Mignone | Teva Pharmaceutical Industries | 47 | |
| Sagi Kabla | Tower Semiconductor | 38 | |
| Michael Berelowitz | Kamada | 74 | |
| Richard Lerner | Teva Pharmaceutical Industries | 76 | |
| Asaf Frumerman | Kamada | N/A | |
Management Performance
| Return On Equity | -0.19 | |||
| Return On Asset | -0.0659 |
Opko Health Leadership Team
Elected by the shareholders, the Opko Health's board of directors comprises two types of representatives: Opko Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Opko. The board's role is to monitor Opko Health's management team and ensure that shareholders' interests are well served. Opko Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Opko Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arie Gutman, Pres API | ||
| Richard Lerner, Independent Director | ||
| Dmitry Kolosov, Independent Director | ||
| Thomas Nusbickel, Chief Commercial Officer of the Company's Renal Division | ||
| Elias MD, Pres Chairman | ||
| Richard Pfenniger, Independent Director | ||
| Philip Frost, Chairman of the Board, CEO | ||
| Thomas Beier, Director | ||
| Akhtar Ashfaq, Senior Vice President - Clinical Research and Development of OPKO Health's Renal Division | ||
| Jon Cohen, Executive Chairman of BioReference Laboratories | ||
| Robert Fishel, Independent Director | ||
| Robert Baron, Independent Director | ||
| Anne Fields, IR Contact Officer | ||
| Adam Logal, CFO, Chief Accounting Officer, Sr. VP and Treasurer | ||
| Alice Yu, Independent Director | ||
| Steven Rubin, Executive Vice President - Administration, Director | ||
| JD Esq, Chief Laboratories | ||
| James DeMarco, VP Sales | ||
| John Paganelli, Independent Director | ||
| Phillip Frost, Chairman of the Board, CEO | ||
| Miriam Miller, IR Contact Officer | ||
| MBA MBA, Vice Officer | ||
| Jon MD, Advisor | ||
| Jane Hsiao, Vice Chairman of the Board, Chief Technical Officer | ||
| Geoff Monk, President of BioReference | ||
| Richard Krasno, Independent Director |
Opko Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Opko Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.19 | |||
| Return On Asset | -0.0659 | |||
| Profit Margin | (0.26) % | |||
| Operating Margin | (0.20) % | |||
| Current Valuation | 3.9 B | |||
| Shares Outstanding | 772.69 M | |||
| Shares Owned By Insiders | 45.87 % | |||
| Shares Owned By Institutions | 24.36 % | |||
| Price To Book | 0.63 X | |||
| Price To Sales | 2.78 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Opko Health in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Opko Health's short interest history, or implied volatility extrapolated from Opko Health options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Opko Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Opko Stock refer to our How to Trade Opko Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for Opko Stock analysis
When running Opko Health's price analysis, check to measure Opko Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opko Health is operating at the current time. Most of Opko Health's value examination focuses on studying past and present price action to predict the probability of Opko Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opko Health's price. Additionally, you may evaluate how the addition of Opko Health to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |